|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Leishmania_spp.
gptkb:Leishmania
|
|
gptkbp:activities
|
binds to ergosterol in fungal cell membranes
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Am_Bisome
gptkb:Fungizone
|
|
gptkbp:can_be_used_with
|
gptkb:flucytosine
azole antifungals
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to amphotericin B
|
|
gptkbp:developed_by
|
gptkb:Merck_&_Co.
gptkb:Streptomyces_nodosus
|
|
gptkbp:discovered_by
|
1950s
|
|
gptkbp:dissolved
|
soluble in organic solvents
poorly soluble in water
|
|
gptkbp:duration
|
several weeks to months
|
|
gptkbp:excretion
|
primarily through urine
|
|
gptkbp:financial_performance
|
stable for 24 months
|
|
gptkbp:formulation
|
liposomal
deoxycholate
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
amphotericin B
|
|
gptkbp:ingredients
|
C47 H73 N1 O17
|
|
gptkbp:interacts_with
|
gptkb:digoxin
corticosteroids
azoles
|
|
gptkbp:is_available_on
|
oral formulation
topical formulation
|
|
gptkbp:is_effective_against
|
gptkb:Aspergillus_species
gptkb:Candida_species
gptkb:Coccidioides_immitis
gptkb:Cryptococcus_neoformans
gptkb:Histoplasma_capsulatum
|
|
gptkbp:is_used_for
|
treatment of fungal infections
|
|
gptkbp:lifespan
|
15 days
|
|
gptkbp:research_focus
|
combination therapies
resistance mechanisms
new formulations
|
|
gptkbp:side_effect
|
gptkb:fandom
headache
nausea
fever
rash
chills
hypokalemia
hypotension
nephrotoxicity
thrombophlebitis
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:used_in
|
cancer patients
immunocompromised patients
HIV/ AIDS patients
|
|
gptkbp:weight
|
924.1 g/mol
|